<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type='text/xsl' href='/w/ProjectMundo-Anon-106A/style/jats-html.xsl'?>
<!DOCTYPE response>
<article article-type="research-article" dtd-version="1.2" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    41467
   </journal-id>
   <journal-id journal-id-type="doi">
    10.1038/41467.2041-1723
   </journal-id>
   <journal-title-group>
    <journal-title>
     Nature Communications
    </journal-title>
    <abbrev-journal-title abbrev-type="publisher">
     Nat Commun
    </abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2041-1723
   </issn>
   <publisher>
    <publisher-name>
     Nature Publishing Group UK
    </publisher-name>
    <publisher-loc>
     London
    </publisher-loc>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">
    s41467-023-44276-x
   </article-id>
   <article-id pub-id-type="manuscript">
    44276
   </article-id>
   <article-id pub-id-type="doi">
    10.1038/s41467-023-44276-x
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Article
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/499
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/699/255/2514
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/326/596/4130
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/326/596/2562
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /141
     </subject>
    </subj-group>
    <subj-group subj-group-type="NatureArticleTypeID">
     <subject>
      article
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">
     Hatari ya kifo cha COVID-19 kwa watu wazima waliopokea chanjo ya nyongeza ya COVID-19 nchini Uingereza
    </article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" corresp="yes" id="Au1">
     <name name-style="western">
      <surname>
       Ward
      </surname>
      <given-names>
       Isobel L.
      </given-names>
     </name>
     <address>
      <email>
       Isobel.Ward@ons.gov.uk
      </email>
     </address>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="corresp" rid="IDs4146702344276x_cor1">
      a
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au2">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-6848-5241
     </contrib-id>
     <name name-style="western">
      <surname>
       Robertson
      </surname>
      <given-names>
       Chris
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au3">
     <name name-style="western">
      <surname>
       Agrawal
      </surname>
      <given-names>
       Utkarsh
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au4">
     <name name-style="western">
      <surname>
       Patterson
      </surname>
      <given-names>
       Lynsey
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au5">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-1468-1823
     </contrib-id>
     <name name-style="western">
      <surname>
       Bradley
      </surname>
      <given-names>
       Declan T.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au6">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-4101-4535
     </contrib-id>
     <name name-style="western">
      <surname>
       Shi
      </surname>
      <given-names>
       Ting
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au7">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-8553-2641
     </contrib-id>
     <name name-style="western">
      <surname>
       de Lusignan
      </surname>
      <given-names>
       Simon
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au8">
     <name name-style="western">
      <surname>
       Hobbs
      </surname>
      <given-names>
       F. D. Richard
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au9">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-7022-3056
     </contrib-id>
     <name name-style="western">
      <surname>
       Sheikh
      </surname>
      <given-names>
       Aziz
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au10">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-0160-217X
     </contrib-id>
     <name name-style="western">
      <surname>
       Nafilyan
      </surname>
      <given-names>
       Vahé
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
    </contrib>
    <aff id="Aff1">
     <label>
      1
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/021fhft25
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.426100.1
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2157 6840
      </institution-id>
      <institution content-type="org-name">
       Office for National Statistics
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Newport
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff2">
     <label>
      2
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/00n3w3b69
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.11984.35
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2113 8138
      </institution-id>
      <institution content-type="org-division">
       Department of Mathematics and Statistics
      </institution>
      <institution content-type="org-name">
       Strathclyde University
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Glasgow
     </addr-line>
     <country country="GB">
      Scotland
     </country>
    </aff>
    <aff id="Aff3">
     <label>
      3
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/023wh8b50
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.508718.3
      </institution-id>
      <institution content-type="org-name">
       Public Health Scotland
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Glasgow
     </addr-line>
     <country country="GB">
      Scotland
     </country>
    </aff>
    <aff id="Aff4">
     <label>
      4
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/052gg0110
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.4991.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 8948
      </institution-id>
      <institution content-type="org-division">
       Nuffield Department of Primary Care Health Sciences
      </institution>
      <institution content-type="org-name">
       University of Oxford
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Oxford
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff5">
     <label>
      5
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/00hswnk62
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.4777.3
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0374 7521
      </institution-id>
      <institution content-type="org-division">
       Centre for Public Health
      </institution>
      <institution content-type="org-name">
       Queen’s University Belfast
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Belfast
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff6">
     <label>
      6
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/03ek62e72
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.454053.3
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0494 5490
      </institution-id>
      <institution content-type="org-name">
       Public Health Agency
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Belfast
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff7">
     <label>
      7
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/01nrxwf90
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.4305.2
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 7988
      </institution-id>
      <institution content-type="org-division">
       Usher Institute
      </institution>
      <institution content-type="org-name">
       University of Edinburgh
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Edinburgh
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff8">
     <label>
      8
     </label>
     <institution-wrap>
      <institution content-type="org-division">
       NIHR Applied Research Collaboration
      </institution>
      <institution content-type="org-name">
       Oxford Thames Valley
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Oxford
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
   </contrib-group>
   <author-notes>
    <corresp id="IDs4146702344276x_cor1">
     <label>
      a
     </label>
     <email>
      Isobel.Ward@ons.gov.uk
     </email>
    </corresp>
   </author-notes>
   <pub-date date-type="pub" publication-format="electronic">
    <day>
     16
    </day>
    <month>
     1
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <pub-date date-type="collection" publication-format="electronic">
    <month>
     12
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <volume>
    15
   </volume>
   <issue seq="398">
    1
   </issue>
   <elocation-id>
    398
   </elocation-id>
   <history>
    <date date-type="registration">
     <day>
      6
     </day>
     <month>
      12
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="received">
     <day>
      20
     </day>
     <month>
      7
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="accepted">
     <day>
      6
     </day>
     <month>
      12
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="online">
     <day>
      16
     </day>
     <month>
      1
     </month>
     <year>
      2024
     </year>
    </date>
   </history>
   <permissions>
    <copyright-statement content-type="compact">
     © Crown 2024
    </copyright-statement>
    <copyright-year>
     2024
    </copyright-year>
    <copyright-holder>
     Crown
    </copyright-holder>
    <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
     <license-p>
      <bold>
       Open Access
      </bold>
      This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
      <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
       http://creativecommons.org/licenses/by/4.0/
      </ext-link>
      .
     </license-p>
    </license>
   </permissions>
   <abstract id="Abs1" xml:lang="en">
    <title>
     Muhtasari
    </title>
    <p id="Par1">
     Kuibuka kwa chanjo ya COVID-19 kumekuwa muhimu katika kubadilisha mwelekeo wa janga la COVID-19. Ili kuhakikisha ulinzi unabaki juu katika makundi yaliyo hatarini, chanjo za nyongeza nchini Uingereza zimeelekezwa kulingana na umri na udhaifu wa kiafya. Tulifanya utafiti wa kitaifa wa kikundi cha nyuma kwa kutumia data kutoka Sensa ya 2021 iliyounganishwa na rekodi za afya za kielektroniki. Tulitumia mifano maalum ya Cox kuchunguza uhusiano kati ya hali za kiafya na hatari ya kifo cha COVID-19 na vifo vingine vyote kwa watu wazima wenye umri wa miaka 50-100 nchini Uingereza waliopokea chanjo ya nyongeza katika msimu wa vuli 2022. Hapa tunaonyesha, kuwa na ulemavu wa kujifunza au Down Syndrome (uwiano wa hatari=5.07;95% muda wa kujiamini=3.69-6.98), shinikizo la damu la mapafu au fibrosis (2.88;2.43-3.40), ugonjwa wa neva za motor, multiple sclerosis, myasthenia au ugonjwa wa Huntington (2.94, 1.82-4.74), saratani ya damu na uboho (3.11;2.72-3.56), ugonjwa wa Parkinson (2.74;2.34-3.20), saratani ya mapafu au mdomo (2.57;2.04 hadi 3.24), shida ya akili (2.64;2.46 hadi 2.83) au cirrhosis ya ini (2.65;1.95 hadi 3.59) ilihusishwa na hatari kubwa ya kifo cha COVID-19. Watu wenye saratani ya damu au uboho, ugonjwa sugu wa figo, cystic fibrosis, shinikizo la damu la mapafu au fibrosis, au arthritis ya rheumatoid au systemic lupus erythematosus walikuwa na hatari kubwa zaidi ya kifo cha COVID-19 ikilinganishwa na sababu nyingine za kifo ikilinganishwa na watu ambao hawakuwa na utambuzi. Watunga sera wanapaswa kuendelea kuzipa kipaumbele makundi yaliyo hatarini kwa dozi za nyongeza za COVID-19 zinazofuata ili kupunguza hatari ya kifo cha COVID-19.
    </p>
   </abstract>
   <abstract abstract-type="ShortSummary" id="Abs2" xml:lang="en">
    <p id="Par2">
     Ward et al. utilise electronic health records to identify groups of adults (who had received a second booster dose of a COVID-19 vaccine) at elevated risk of COVID-19 death.
    </p>
   </abstract>
   <kwd-group kwd-group-type="hierarchical" vocab="FoR" vocab-identifier="ANZSRC 2008">
    <kwd content-type="term" vocab-term-identifier="11">
     Medical and Health Sciences
    </kwd>
    <nested-kwd>
     <kwd content-type="term" vocab-term-identifier="1117">
      Public Health and Health Services
     </kwd>
    </nested-kwd>
   </kwd-group>
   <custom-meta-group>
    <custom-meta>
     <meta-name>
      publisher-imprint-name
     </meta-name>
     <meta-value>
      Nature Portfolio
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-issue-count
     </meta-name>
     <meta-value>
      1
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-article-count
     </meta-name>
     <meta-value>
      398
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-pricelist-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-holder
     </meta-name>
     <meta-value>
      Springer Nature Limited
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-contains-esm
     </meta-name>
     <meta-value>
      Yes
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-year
     </meta-name>
     <meta-value>
      2023
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-month
     </meta-name>
     <meta-value>
      12
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-day
     </meta-name>
     <meta-value>
      6
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-product
     </meta-name>
     <meta-value>
      NonStandardArchiveJournal
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-grants-type
     </meta-name>
     <meta-value>
      OpenChoice
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      metadata-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      abstract-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodypdf-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodyhtml-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bibliography-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      esm-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      online-first
     </meta-name>
     <meta-value>
      false
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-file-reference
     </meta-name>
     <meta-value>
      BodyRef/PDF/41467_2023_Article_44276.pdf
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-type
     </meta-name>
     <meta-value>
      Typeset
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      target-type
     </meta-name>
     <meta-value>
      OnlinePDF
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-type
     </meta-name>
     <meta-value>
      OriginalPaper
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-primary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-collection
     </meta-name>
     <meta-value>
      Science (multidisciplinary)
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      open-access
     </meta-name>
     <meta-value>
      true
     </meta-value>
    </custom-meta>
   </custom-meta-group>
  </article-meta>
 </front>
 <body>
  <sec id="Sec1" sec-type="introduction">
   <title>
    Utangulizi
   </title>
   <p id="Par3">
    Maendeleo na usambazaji wa chanjo za COVID-19 yamepunguza kwa kiasi kikubwa maambukizi makali ya COVID-19, maradhi, na vifo
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
    </sup>
    . Hata hivyo, baadhi ya makundi ya wagonjwa walibaki katika hatari kubwa ya kifo cha COVID-19 licha ya kupokea mfululizo wa chanjo ya msingi. Aidha, ufanisi umeonekana kupungua kwa muda
    <sup>
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
    </sup>
    . Kwa sababu hiyo, dozi za nyongeza zilihitajika ili kuhakikisha kuwa idadi ya watu inabaki salama dhidi ya matokeo makali, hasa wakati vizuizi vya kudhibiti maambukizi vimeondolewa. Nchini Uingereza, dozi za kwanza za nyongeza zilitolewa kwa kila mtu mzima miezi mitatu baada ya kupokea dozi ya pili ya chanjo ya COVID-19
    <sup>
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
    </sup>
    . Dozi za nyongeza zilizofuata zilitolewa kwa makundi yaliyo katika hatari kubwa ya kulazwa hospitalini au kifo, kama vile watu wazima wakubwa, watu wenye hali fulani za kiafya, au watu waliokuwa na mawasiliano na wagonjwa walio hatarini, kama vile wafanyakazi wa afya
    <sup>
     <xref ref-type="bibr" rid="CR4">
      4
     </xref>
    </sup>
    .
   </p>
   <p id="Par4">
    Kuendelea kuwalinda watu walio hatarini zaidi dhidi ya COVID-19 ni muhimu ili kupunguza athari za moja kwa moja na zisizo za moja kwa moja za SARS-CoV-2 kwenye afya ya umma na huduma za afya, hasa wakati nchi nyingi zinapobadilika kwenda kwenye usimamizi wa muda mrefu wa janga la COVID-19
    <sup>
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
    </sup>
    . Kutambua wagonjwa walio katika hatari kubwa ya matokeo makali kutokana na maambukizi ya SARS-CoV-2 ni muhimu ili kuhakikisha kuwa dozi za nyongeza zinatolewa kwa wale wanaozihitaji huku wakidhibiti gharama za mpango wa chanjo. Ushahidi uliopo unaonyesha kuwa kando na umri, kuwa na magonjwa yanayoambatana na hali maalum kama vile ugonjwa sugu wa figo (CKD) kunahusishwa na hatari kubwa ya kulazwa hospitalini na kifo cha COVID-19 kwa watu waliopokea ratiba kamili ya chanjo na dozi ya kwanza ya nyongeza
    <sup>
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
    </sup>
    . Hata hivyo, kuna ushahidi mdogo juu ya sababu za hatari za kifo cha COVID-19 kwa watu waliopokea chanjo ya nyongeza ya pili katika msimu wa vuli wa 2022 nchini Uingereza. Kuelewa hatari kwa makundi tofauti ya watu ni muhimu ili kuarifu Kamati ya Pamoja ya Chanjo na Kinga (JCVI) nchini Uingereza na vyombo vya kimataifa vinavyolingana katika kufanya maamuzi juu ya kipaumbele cha chanjo za nyongeza zinazofuata.
   </p>
   <p id="Par5">
    Katika utafiti huu, tulilenga kutambua makundi ya watu wazima ambao walikuwa katika hatari kubwa ya kifo cha COVID-19, miongoni mwa wale waliopokea dozi ya pili ya nyongeza ya chanjo ya COVID-19 kama sehemu ya kampeni ya nyongeza ya vuli ya 2022 ya Uingereza. Tukitumia seti ya data iliyounganishwa kulingana na Sensa ya 2021 iliyounganishwa na rekodi za huduma za msingi na data za usajili wa vifo, tulikadiria uwiano wa hatari ya kifo kinachohusisha COVID-19 kwa anuwai ya sifa za kijamii na kiuchumi na sababu za hatari za kiafya. Pia tulikadiria uwiano wa hatari ya kifo kisichohusisha COVID-19, ili kuelewa ni makundi gani yalikuwa katika hatari kubwa ya kifo cha COVID-19 lakini yalikuwa na hatari ndogo ya kifo kwa ujumla
    <sup>
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
    </sup>
    .
   </p>
  </sec>
  <sec id="Sec2" sec-type="results">
   <title>
    Matokeo
   </title>
   <p id="Par6">
    Kulikuwa na watu wazima 14,651,440 wenye umri wa miaka 50-100 katika idadi ya watu wa utafiti wetu (wastani = miaka 67.9, tofauti ya kawaida (SD) = 10.9); 46.9% walikuwa wanaume na 90.4% walikuwa Waingereza Weupe. Tabia za kimaelezo za idadi ya watu wa utafiti zimeripotiwa katika Data ya Ziada
    <xref ref-type="supplementary-material" rid="MOESM4">
     1
    </xref>
    <sup/>
    . Kati ya Septemba 1, 2022, na Aprili 11, 2023, kulikuwa na vifo 6,800 vya COVID-19 (52.2% wanaume), na vifo 150,075 visivyo vya COVID-19, 1 (48.4% wanaume). Umri wa wastani wa wale waliokufa kutokana na COVID-19 ulikuwa miaka 84.0 (SD = 8.87) na kwa vifo visivyo vya COVID-19 ulikuwa miaka 82.3 (SD = 9.85).
   </p>
   <p id="Par7">
    Umri ulikuwa kiashiria muhimu cha vifo vya COVID-19 na visivyo vya COVID-19; hatari ilikuwa mara 46 kubwa zaidi kwa mtu wa miaka 80 ikilinganishwa na mtu wa miaka 50 kwa kifo kinachohusiana na COVID-19 (HR:46.4;95%CI:43.0–50.0), na mara 30 kubwa zaidi kwa kifo kisichohusiana na COVID-19 (HR:29.6; 95%CI:29.2–30.0) (Fig.
    <xref ref-type="fig" rid="Fig1">
     1
    </xref>
    , Data ya Ziada
    <xref ref-type="supplementary-material" rid="MOESM5">
     2
    </xref>
    ). Wanawake walikuwa na hatari ndogo ya kifo cha COVID-19 (HR:0.63; 95%CI 0.6–0.66) na kifo kisicho cha COVID-19 (HR:0.76; 95%CI:0.75–0.77) ikilinganishwa na wanaume (Model 1) (Data ya Ziada
    <xref ref-type="supplementary-material" rid="MOESM5">
     2
    </xref>
    ). Tuligundua hatari ndogo sana ya vifo vya COVID-19 kwa Wakaribiani Weusi (HR:0.46; 95%CI:0.29–0.73), Wahindi (HR:0.75;95%CI:0.58–0.95) na kundi lingine la kikabila (HR:0.62;95%CI:0.45–0.87) ikilinganishwa na kundi la Waingereza Weupe kwa matokeo ya COVID-19 (Model 2) (Data ya Ziada
    <xref ref-type="supplementary-material" rid="MOESM5">
     2
    </xref>
    ). Kuwa na uzito mkubwa kupita kiasi au uzito mdogo kunahusishwa na hatari kubwa ya COVID-19 (Uzito mkubwa kupita kiasi = HR:1.60;95%CI:1.35–1.89, Uzito mdogo = HR:2.29;95%CI:2.04–2.59) na kifo kisicho cha COVID-19 (Uzito mkubwa kupita kiasi = HR:1.55;95%CI:1.50–1.60, Uzito mdogo = HR:2.45;95%CI:2.39–2.51) (Model 3) (Data ya Ziada
    <xref ref-type="supplementary-material" rid="MOESM5">
     2
    </xref>
    ). Kujiripoti kuwa na ulemavu ambao ulipunguza shughuli za kila siku za mtu kidogo au sana kulihusishwa na hatari kubwa ya vifo vya COVID-19 na visivyo vya COVID-19 ikilinganishwa na watu wasio na ulemavu (Model 4) (Data ya Ziada
    <xref ref-type="supplementary-material" rid="MOESM5">
     2
    </xref>
    ).
    <fig id="Fig1" position="float">
     <label>
      Fig. 1
     </label>
     <caption xml:lang="en">
      <title>
       Uhusiano kati ya umri na hatari ya kifo kutokana na COVID-19.
      </title>
      <p>
       Uwiano wa hatari (HRs) ulitolewa kwa kutumia mfano wa Cox wa urejeleaji ambao ulirekebishwa kwa umri, jinsia na muda wa kalenda. HR ya rejeleo ni kwa mwanaume wa miaka 50. Matokeo ya COVID-19 yanaonyeshwa kwa rangi nyekundu na matokeo yasiyo ya COVID-19 yanaonyeshwa kwa rangi ya bluu. Eneo lenye kivuli karibu na mistari linaonyesha kiwango cha kujiamini cha asilimia 95.
      </p>
     </caption>
     <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-023-44276-x/41467_2023_44276_Fig1_HTML.png" mime-subtype="PNG" specific-use="web"/>
    </fig>
   </p>
   <p id="Par8">
    Kwa ujumla, hali zilizo na hatari kubwa zaidi ya kifo cha COVID-19 ikilinganishwa na kutokuwa na hali hiyo (HR &gt; 2) zilikuwa watu wenye ulemavu wa kujifunza au Down’s syndrome (HR:5.07;95%CI:3.69–6.98), wale wenye shinikizo la damu la mapafu au fibrosis (HR:2.88;95%CI:2.43-3.40), ugonjwa wa neva za motor, multiple sclerosis, myasthenia au ugonjwa wa Huntington (HR:2.94;95%CI:1.82–4.74), saratani ya damu na uboho (HR:3.11;95%CI:2.72-3.56), ugonjwa wa Parkinson (HR:2.74;95%CI:2.34–3.20), saratani ya mapafu au mdomo (HR:2.57:95%CI:2.04–3.24), dementia (HR:2.64;95%CI:2.46–2.83), au cirrhosis ya ini (HR:2.65;95%CI:1.95–3.59) (Fig.
    <xref ref-type="fig" rid="Fig2">
     2
    </xref>
    , Data ya Ziada
    <xref ref-type="supplementary-material" rid="MOESM5">
     2
    </xref>
    ).
    <fig id="Fig2" position="float">
     <label>
      Fig. 2
     </label>
     <caption xml:lang="en">
      <title>
       Vihatarishi vya kifo kutokana na COVID-19 na visivyo vya COVID-19 kwa watu wazima waliopata chanjo ya nyongeza.
      </title>
      <p>
       Uwiano wa hatari (HRs) ulitolewa kwa kutumia mfano wa Cox wa urejeleaji ambao ulirekebishwa kwa umri, jinsia, muda wa kalenda, kabila, eneo na hali zote za kiafya (Mfano 5). Mistari iliyokatika inaonyesha HR ya 1. Rejeleo kwa hali zote ni kutokuwa na utambuzi wa hali maalum. Matokeo ya COVID-19 yanaonyeshwa kwa rangi ya kijani na matokeo yasiyo ya COVID-19 yanaonyeshwa kwa rangi ya zambarau. HR inaonyeshwa na nukta na mistari inaonyesha kiwango cha kujiamini cha asilimia 95.
      </p>
     </caption>
     <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-023-44276-x/41467_2023_44276_Fig2_HTML.png" mime-subtype="PNG" specific-use="web"/>
    </fig>
   </p>
   <p id="Par9">
    Ikilinganishwa na HR za vifo vya COVID-19 na visivyo vya COVID-19, tuligundua hatari kubwa ya jamaa ya kifo cha COVID-19 ikilinganishwa na kifo kisicho cha COVID-19 kwa hali zifuatazo: saratani ya damu au uboho wa mfupa, CKD, cystic fibrosis, shinikizo la chini la damu la mapafu au fibrosis au arthritis ya rheumatoid au systemic lupus erythematosus (SLE) (Jedwali la nyongeza
    <xref ref-type="supplementary-material" rid="MOESM1">
     2
    </xref>
    ). Kinyume chake, tuligundua hatari ya jamaa ya kufa kutokana na sababu zisizo za COVID-19 ilikuwa kubwa kuliko vifo vya COVID-19 kwa dementia na cirrhosis ya ini ikilinganishwa na wale ambao hawana hali hizi.
   </p>
   <p id="Par10">
    Katika mfano wa nyongeza ambao haujarekebishwa kwa magonjwa mengine ya kiafya, hatari ya matokeo ya COVID-19 ilikuwa imeongezeka ikilinganishwa na mfano ambapo hali zingine zilirekebishwa (Jedwali la nyongeza
    <xref ref-type="supplementary-material" rid="MOESM1">
     3
    </xref>
    ). Inashangaza, kwa pumu katika mfano uliorekebishwa kwa hali zingine za kiafya (Mfano 5) HR kwa matokeo ya COVID-19 ilikuwa chini ya 1 (HR:0.84;95%CI:0.77-0.95), hata hivyo katika mfano wa nyongeza (uliorekebishwa kwa jinsia, umri, eneo, kundi la kikabila, na wakati wa kalenda) hatari ilikuwa kubwa zaidi kwa watu waliogunduliwa na pumu ikilinganishwa na wasio na (HR:1.22;95%CI:1.11-1.33) (Jedwali la nyongeza
    <xref ref-type="supplementary-material" rid="MOESM1">
     3
    </xref>
    ).
   </p>
  </sec>
  <sec id="Sec3" sec-type="discussion">
   <title>
    Majadiliano
   </title>
   <p id="Par11">
    Uchunguzi huu wa kitaifa umebaini watu wazima ambao walibaki katika hatari kubwa ya kifo cha COVID-19 baada ya kupokea chanjo ya nyongeza ya dozi ya pili nchini Uingereza katika Majira ya Kupukutika 2022. Matokeo yetu yanaonyesha kuwa kuwa na ulemavu wa kujifunza au Down’s syndrome, shinikizo la juu la damu la mapafu au fibrosis, ugonjwa wa neva wa motor, multiple sclerosis, myasthenia au ugonjwa wa Huntington, saratani ya damu na uboho wa mfupa, ugonjwa wa Parkinson, saratani ya mapafu au mdomo, dementia au cirrhosis ya ini vilihusishwa kwa uhuru na hatari kubwa ya kifo kinachohusiana na COVID-19. Kwa saratani ya damu au uboho wa mfupa, CKD, cystic fibrosis, shinikizo la chini la damu la mapafu au fibrosis au arthritis ya rheumatoid au SLE ongezeko la hatari ya jamaa lilikuwa kubwa zaidi kwa kifo cha COVID-19 kuliko kifo kisicho cha COVID-19. Matokeo yetu yanapendekeza watu katika makundi hayo walikuwa hasa katika hatari ya kifo cha COVID-19 ikilinganishwa na sababu nyingine za kifo. Kwa mfano, kwa watu wenye arthritis ya rheumatoid au SLE, hatari ya kufa kutokana na sababu zisizo za COVID-19 haikuwa tofauti sana na watu wasio na utambuzi huu; hata hivyo, hatari ilikuwa kubwa kwa kifo cha COVID-19. Muhimu, kundi hili halikutambuliwa kama moja ya magonjwa ya kiafya yaliyoorodheshwa yenye hatari kubwa zaidi ya kifo cha COVID-19, lakini uchambuzi wetu unaangazia umuhimu wa hatari ya jamaa na watu kuwa na uwezekano mkubwa wa kufa kutokana na COVID-19 katika kundi hili ikilinganishwa na sababu nyingine.
   </p>
   <p id="Par12">
    Kwa hali nyingi za kiafya ongezeko la hatari ya kifo cha COVID-19 lilikuwa sawa na, au chini kuliko, ongezeko la hatari ya vifo visivyo vya COVID-19, ikionyesha kuwa ongezeko la hatari ya kifo cha COVID-19 halikuwa tofauti na ongezeko la hatari ya kifo kutokana na sababu nyingine. Ingawa tunagundua kuwa wagonjwa wenye pumu walikuwa katika hatari kubwa ya kifo cha COVID-19 baada ya kuzingatia umri, jinsia, kundi la kikabila na eneo, tuligundua kuwa kuwa na pumu hakuhusiani na hatari ya kifo cha COVID-19 baada ya kurekebisha kwa magonjwa mengine, ikionyesha kuwa pumu haikuongeza moja kwa moja hatari ya kifo cha COVID-19.
   </p>
   <p id="Par13">
    Matokeo yetu yanaunga mkono utafiti wa awali ambao umechunguza matokeo ya vifo kufuatia chanjo za nyongeza za dozi ya kwanza ya COVID-19
    <sup>
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
    </sup>
    . Kwa ujumla, nchini Uingereza chanjo za nyongeza za dozi ya kwanza zimeonekana kupunguza matokeo makali (kulazwa hospitalini na kifo), huku makundi maalum yakibaki katika hatari kubwa
    <sup>
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
    </sup>
    . Watu wazima wazee (zaidi ya miaka 80), wale wenye magonjwa ya kiafya na hali maalum kama CKD walionekana kuwa katika hatari kubwa. Utafiti uliofanywa nchini Marekani ulibaini kuwa kwa wagonjwa ambao walikuwa na upungufu wa kinga, kisukari, walikuwa na CKD au ugonjwa sugu wa mapafu kulikuwa na ongezeko la hatari ya maambukizi ya COVID-19 yanayovunja kinga yaliyounganishwa vyema na idadi ya magonjwa yanayofuatia dozi mbili za msingi
    <sup>
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
    </sup>
    . Ni muhimu kuzingatia kuwa matokeo yaliyowasilishwa katika utafiti wetu yanaweza yasioneshe tofauti katika hatari ya kifo cha COVID-19 kufuatia maambukizi. Utafiti wetu unatazama hatari ya kifo tangu wakati wa kupokea dozi ya pili ya nyongeza, si tangu maambukizi. Inawezekana kuwa hatari ya maambukizi pia inatofautiana na sababu za hatari za kiafya, kwani wagonjwa ambao wako katika hatari kubwa wanaweza kudumisha kujitenga kijamii ili kujilinda. Pia inawezekana kuwa baadhi ya wagonjwa walio katika hatari kubwa wanaweza kuwa katika hatari kubwa ya maambukizi kwa sababu wanaishi katika makazi ya pamoja au wana mawasiliano ya mara kwa mara na walezi au wafanyakazi wa matibabu.
   </p>
   <p id="Par14">
    Kwa umuhimu, kazi yetu inatathmini athari za chanjo ya nyongeza ya majira ya kupukutika 2022 kwenye COVID-19, lakini pia matokeo yasiyo ya COVID-19 kwa watu wazima nchini Uingereza. Matokeo yetu yanatoa ushahidi thabiti wa kuarifu JCVI kuhusu ni makundi gani yanapaswa kupewa kipaumbele kwa nyongeza zinazofuata na labda nyongeza zinazofuata. Ni muhimu kuangazia ukweli kwamba baadhi ya makundi ambayo hayana hatari kubwa zaidi ya kifo cha COVID-19, yana hatari iliyoongezeka ikilinganishwa na sababu zisizo za COVID-19 na hivyo yanapaswa kubaki kuwa kipaumbele muhimu.
   </p>
   <p id="Par15">
    Utafiti wetu una nguvu kadhaa. Kwanza, tulitumia data ya kiwango cha idadi ya watu kwa Uingereza kulingana na uhusiano wa kipekee wa Sensa ya 2021 na rekodi za afya za kielektroniki. Tabia za kijamii na kiuchumi, ikiwa ni pamoja na kundi la kikabila, zilitokana na Sensa ya 2021, na zilikuwa sahihi na zilikuwa na upungufu mdogo, tofauti na katika baadhi ya rekodi za afya za kielektroniki, ambapo kundi la kikabila mara nyingi hukosekana na si mara zote huripotiwa binafsi
    <sup>
     <xref ref-type="bibr" rid="CR10">
      10
     </xref>
    </sup>
    . Pili, tulitambua sababu za hatari za kiafya kwa kutumia data ya huduma ya msingi. Tatu, tulitumia taarifa juu ya sababu ya kifo kufafanua kifo cha COVID-19 na pia tuliweza kuchunguza kifo kisicho cha COVID-19 kama mlinganisho na kutambua hali zipi zilihusishwa na hatari iliyoongezeka kwa kifo cha COVID-19 kuliko kifo kisicho cha COVID-19.
   </p>
   <p id="Par16">
    Kizuizi muhimu cha utafiti wetu ni matumizi ya Sensa ya 2021 kwa idadi yetu ya watu inamaanisha kwamba watu ambao hawakujibu Sensa walitengwa. Aidha, pia ilitenga wahojiwa wa Sensa ambao hawakuweza kuunganishwa na Huduma ya Demografia ya Kibinafsi (PDS). Hata hivyo, data tuliyotumia ilifunika 96.0% ya wale waliopokea dozi ya nyongeza nchini Uingereza katika msimu wa vuli wa 2022. Moja ya vikwazo vya kazi yetu ilikuwa ukosefu wa data juu ya kulazwa hospitalini kwa COVID-19
    <sup>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
    </sup>
    . Ili kusimamia rasilimali kwa ufanisi na kuelewa ni makundi gani yako katika hatari kubwa ya kulazwa hospitalini, kazi inayofuata yenye ufikiaji wa data kwa wakati inapaswa kuzingatia kulazwa hospitalini. Zaidi ya hayo, hatuwezi kuzingatia tabia ambazo zingeainishwa kama kinga ya afya kama vile kupunguza mawasiliano ya kijamii katika utafiti huu. Kwa hiyo, ni muhimu kuzingatia kwa baadhi ya wagonjwa ambao hatari yao ya kulazwa hospitalini au kifo ilikuwa muhimu zaidi baada ya maambukizi ya SARS-CoV-2, wanaweza kuwa wanadumisha kujitenga kwa kijamii ili kujilinda. Kwa hivyo kwa makundi ya watu ambapo hatari haikuwa kubwa kwa matokeo ya COVID-19, lakini kwa ujumla ilikuwa kubwa kwa vifo vya sababu zote tunapaswa kudumisha kipaumbele cha chanjo kwa watu hawa. Utafiti unaofuata unapaswa kuchunguza hali za kawaida (mfano, pumu) ili kuelewa ikiwa mwingiliano kati ya kuwa na utambuzi wa kawaida pamoja na hali nyingine maalum husababisha uwezekano wa kupata matokeo mabaya ya COVID-19.
   </p>
   <p id="Par17">
    Kazi yetu inachunguza hatari ya kifo cha COVID-19 kinachosababishwa na sababu maalum, pamoja na kifo kisicho cha COVID-19 katika kundi la watu wazima waliopokea dozi ya nyongeza katika msimu wa vuli wa 2022. Ili kusimamia hatari ya COVID-19 kwa ufanisi, ni muhimu kwamba makundi ya watu walio katika hatari kubwa zaidi yawe kipaumbele kwa chanjo za nyongeza za COVID-19. Tunasisitiza kwamba hatari ya kifo cha COVID-19, ikilinganishwa na vifo vya sababu nyingine zote, inabaki kuwa juu sana kwa watu wazima wenye ulemavu wa kujifunza au Down syndrome, shinikizo la damu la mapafu au fibrosis, ugonjwa wa neva wa motor, multiple sclerosis, myasthenia au ugonjwa wa Huntington, saratani ya damu na uboho, ugonjwa wa Parkinson, saratani ya mapafu au mdomo, shida ya akili, au cirrhosis ya ini. Makundi haya ya wagonjwa yanapaswa kuwa kipaumbele kikuu kwa chanjo zinazofuata, matibabu, na matibabu mapya. Aidha, tunasisitiza hatari inayohusishwa na hali mbalimbali za kiafya na tabia za kijamii na kiuchumi ambazo zinapaswa kuwajulisha watunga sera na watafiti na demografia muhimu za maslahi kwa utafiti na chanjo zinazofuata.
   </p>
  </sec>
  <sec id="Sec4" sec-type="methods">
   <title>
    Mbinu
   </title>
   <p id="Par18">
    Utafiti huu uliidhinishwa na Kamati ya Ushauri wa Maadili ya Takwimu ya Kitaifa (NSDEC) (Mamlaka ya Takwimu ya Uingereza).
   </p>
   <sec id="Sec5">
    <title>
     Vyanzo vya data
    </title>
    <p id="Par19">
     Tulitumia data ya kiwango cha mtu mmoja mmoja inayojumuisha watu katika Sensa ya 2021, iliyounganishwa na Huduma ya Demografia ya Kibinafsi (PDS), kupata nambari za NHS na kiwango cha uhusiano cha 94.6%. Watu hawa kisha waliunganishwa kupitia nambari ya NHS na usajili wa vifo wa Ofisi ya Takwimu za Kitaifa (ONS) (ikiwa ni pamoja na vifo vilivyosajiliwa hadi Aprili 26, 2023) na rekodi nyingine za afya za kielektroniki. Rekodi za chanjo zilipatikana kutoka kwa Huduma ya Usimamizi wa Chanjo ya Kitaifa (NIMS)
     <sup>
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      <xref ref-type="bibr" rid="CR13">
       13
      </xref>
      <xref ref-type="bibr" rid="CR14">
       14
      </xref>
     </sup>
     . Nchini Uingereza katika msimu wa vuli wa 2022 chanjo zote zilizotolewa kwa watu wazima (miaka 18 na zaidi) zilikuwa dozi za mRNA zilizotolewa na madaktari wa familia, vituo vya chanjo na wafamasia wa jamii. Vigezo vinavyohusiana na afya kutoka kwa rekodi za huduma ya msingi vilitokana na data ya Huduma ya Uchimbaji wa Mazoezi ya Jumla (GPES) kwa Mipango ya Janga na Utafiti toleo la 4 (GDPPR) na kuunganishwa kupitia nambari ya NHS. Seti ya data iliyounganishwa ilijumuisha data ya watu milioni 52 wakazi wa Uingereza, ambayo inashughulikia (ikihesabu uhusiano na wasiojibu) takriban 91.8% ya idadi ya watu wa Uingereza siku ya Sensa mwaka 2021.
    </p>
   </sec>
   <sec id="Sec6">
    <title>
     Idadi ya watu waliohusika katika utafiti
    </title>
    <p id="Par20">
     Utafiti huu ulikuwa utafiti wa kikundi cha nyuma ambao ulijumuisha watu waliopokea dozi ya nyongeza ya COVID-19 nchini Uingereza baada ya Septemba 1, 2022, waliorodheshwa katika Sensa ya 2021, waliounganishwa na PDS, na walikuwa na umri wa miaka 50-100 wakati wa utoaji wa dozi ya nyongeza. Dozi ya nyongeza ya msimu wa vuli ilifafanuliwa kama dozi ya nyongeza iliyotolewa mnamo au baada ya Septemba 1, 2022, na angalau siku 84 tangu dozi ya mwisho inayokubalika kliniki, na watu lazima wawe wamepokea angalau dozi mbili kabla ya nyongeza (Mchoro wa Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     ). Tazama Jedwali la Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     kwa mtiririko wa sampuli.
    </p>
   </sec>
   <sec id="Sec7">
    <title>
     Matokeo
    </title>
    <p id="Par21">
     Matokeo ya msingi ya utafiti huu yalikuwa vifo vya COVID-19, yaliyofafanuliwa kama vifo vyovyote vya Uainishaji wa Kimataifa wa Magonjwa (ICD) vilivyo na misimbo U07.1 na U07.2 iliyorekodiwa popote kwenye cheti cha kifo, ambavyo vilitokea hadi Aprili 11, 2023, na vilisajiliwa kufikia Aprili 26, 2023 (ikitoa siku 15 kwa usajili wa kifo). Matokeo ya pili yalikuwa vifo vyote visivyo vya COVID-19
     <sup>
      <xref ref-type="bibr" rid="CR15">
       15
      </xref>
     </sup>
     .
    </p>
    <p id="Par22">
     Watu walifuatiliwa kuanzia siku 14 baada ya tarehe ya chanjo ya nyongeza ya msimu wa vuli hadi Aprili 11, 2023. Muda wa hatari ulianza siku 14 baada ya chanjo ya nyongeza na kuisha wakati wa kifo (iwe ni COVID-19 au nyingine), au mwisho wa utafiti (Aprili 11, 2023).
    </p>
   </sec>
   <sec id="Sec8">
    <title>
     Uchunguzi
    </title>
    <p id="Par23">
     Vitabiri vilivyojumuishwa katika mfano vilijumuisha sifa za kijamii na kidemografia kutoka Sensa ya 2021 na vigezo vya hatari ya kiafya kutoka data ya huduma ya msingi. Hali za kiafya zilipatikana kwa kutumia rekodi za huduma ya msingi kutoka Huduma ya Uchimbaji wa Mazoezi ya Jumla (GPES) kwa data ya Mipango na Utafiti wa Janga toleo la 4 (GDPPR) kulingana na ufafanuzi uliotumiwa na QCovid2, mfano wa utabiri wa hatari, kwa kutumia data kati ya Machi 1, 2015, na Machi 21, 2021 (siku ya Sensa). Mfano wa utabiri wa hatari wa QCovid ulitumiwa na NHS nchini Uingereza kutambua watu ambao wako katika hatari kubwa ya kulazwa hospitalini na kifo kutokana na COVID-19. Mfano huo umethibitishwa hapo awali kwa kutumia PHDA na data kutoka Scotland
     <sup>
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      <xref ref-type="bibr" rid="CR18">
       18
      </xref>
     </sup>
     . Vitabiri vyote vilivyojumuishwa katika mfano vimeelezwa katika Data ya Ziada
     <xref ref-type="supplementary-material" rid="MOESM4">
      1
     </xref>
     <sup/>
     . Vipengele vilivyokosekana kwa sifa za Sensa vilijazwa kwa kutumia mbinu ya ujazaji wa karibu wa jirani, mbinu iliyotumiwa na ONS katika vigezo vyote vya Sensa ya 2011. Taarifa za Kielezo cha Misa ya Mwili (BMI) zilizokosekana zilishughulikiwa kwa kujumuisha kitengo cha 'Kilichokosekana'.
    </p>
   </sec>
   <sec id="Sec9">
    <title>
     Uchambuzi wa takwimu
    </title>
    <p id="Par24">
     Tulitumia usajili maalum wa Cox kuchunguza uhusiano kati ya kila moja ya magonjwa ya kiafya na hatari ya kifo cha COVID-19 na vifo vyote vingine. Muda wa hatari ulianza siku 14 baada ya kupokea dozi ya nyongeza ya msimu wa vuli na kuisha ama wakati wa kifo au mwisho wa kipindi cha utafiti (Aprili 11, 2023). Kwa kila matokeo (COVID-19 na yasiyo ya COVID-19), kwanza tulifanyia mfano uliorekebishwa kwa umri (spline ya cubic iliyozuiliwa na fundo za mipaka katika asilimia ya 5 na 95 na fundo 3 za ndani), jinsia na wakati wa kalenda (spline ya cubic iliyozuiliwa na fundo za mipaka katika asilimia ya 5 na 95 na fundo 3 za ndani) (Mfano 1), kisha tukajumuisha kundi la kikabila na eneo (Mfano 2), BMI (Mfano 3) na ulemavu (Mfano 4)
     <sup/>
     .
    </p>
    <p id="Par25">
     Kwa kila moja ya magonjwa ya kiafya tulifanyia mfano uliorekebishwa kwa hali zote za kiafya za QCovid, umri (spline), jinsia, wakati wa kalenda (spline), kundi la kikabila na eneo (Mfano 5). Aidha, tulifanyia mifano tofauti kwa kila hali ya kiafya, iliyorekebishwa kwa umri (spline ya cubic iliyozuiliwa), jinsia, wakati wa kalenda (spline ya cubic iliyozuiliwa), kundi la kikabila na eneo. Kwa sababu za kihesabu, uchambuzi ulifanywa kwenye seti ya data iliyo na kila mtu aliyekufa na sampuli yenye uzito wa 5% ya wale walionusurika hadi mwisho wa utafiti. Ili kupima tofauti za hatari kati ya mifano ya COVID-19 na yasiyo ya COVID-19 kwa watu waliokuwa na utambuzi wa magonjwa ya kiafya, takwimu za Z zilihesabiwa kwa kila mgawo kutoka mifano (Mfano 5) na data iliyoboreshwa (mizunguko 1000). Uboreshaji ulifanywa kwenye data iliyosampuliwa kuhakikisha uwiano wa matokeo (kifo na hai) umehifadhiwa. Uchambuzi ulifanywa kwa kutumia Spark toleo la 2.4.0 na R toleo la 3.5.1. Hesabu zote zimezungushwa hadi karibu 5, na thamani chini ya 10 zimefichwa kwa sababu za ufichuzi.
    </p>
   </sec>
   <sec id="Sec10">
    <title>
     Muhtasari wa ripoti
    </title>
    <p id="Par26">
     Taarifa zaidi kuhusu muundo wa utafiti zinapatikana katika
     <xref ref-type="supplementary-material" rid="MOESM6">
      Muhtasari wa Kuripoti wa Nature Portfolio
     </xref>
     ulioambatanishwa na makala hii.
    </p>
   </sec>
  </sec>
 </body>
 <back>
  <ack>
   <title>
    Shukrani
   </title>
   <p>
    Waandishi wangependa kumshukuru Daniel Ayoubkhani kwa utaalamu wao wa takwimu na mwongozo wa kimbinu. Kazi hii imefadhiliwa na UKRI kama sehemu ya tuzo kwa Chuo Kikuu cha Birmingham kwa Mafunzo ya Kitaifa ya Msingi ya COVID-19 (NCS), kwa "Awamu ya 1 Kinga ya COVID-19 - Utafiti wa Kitaifa wa Msingi (Awamu ya 1 IMM-NCS)". Nambari ya rejea ya tuzo ni MC_PC_20061.
   </p>
  </ack>
  <sec sec-type="author-contribution">
   <title>
    Mchango wa waandishi
   </title>
   <p>
    I.W., V.N. na A.S. walibuni na kubuni utafiti. I.W. aliandaa utafiti na kufanya uchambuzi wa takwimu, ambao ulithibitishwa ubora na V.N., I.W., V.N., C.R., na A.S., walichangia katika tafsiri ya matokeo. I.W. na V.N. waliandika rasimu ya awali. UA, LP, DB, TS, SdeL na RH walichangia katika mapitio na uhariri wa hati na waliidhinisha hati ya mwisho.
   </p>
  </sec>
  <sec sec-type="peer-review">
   <title>
    Mapitio ya rika
   </title>
   <sec id="FPar1">
    <title>
     Taarifa za mapitio ya rika
    </title>
    <p id="Par27">
     <italic>
      Nature Communications
     </italic>
     thanks the anonymous, reviewers for their contribution to the peer review of this work. A peer review file is available.
    </p>
   </sec>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Upatikanaji wa data
   </title>
   <p>
    The source data used in this study is subject to controlled access due to its sensitive nature. All statistical data used in this study are available from the Office for National Statistics website.
    <xref ref-type="sec" rid="Sec12">
     Source data
    </xref>
    are provided with this paper.
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Upatikanaji wa msimbo
   </title>
   <p>
    Code used in this study is available on Github [link]
   </p>
  </sec>
  <sec sec-type="ethics-statement">
   <sec id="FPar2" sec-type="COI-statement">
    <title>
     Maslahi yanayokinzana
    </title>
    <p id="Par28">
     SdeL has received University funding for vaccine related research from AstraZeneca, GSK, Moderna, Pfizer, Sanofi, Seqirus, and Takeda, and been advisory board members for AstraZeneca, GSK, Sanofi and Seqirus. The remaining authors declare no competing interests.
    </p>
   </sec>
  </sec>
  <ref-list id="Bib1">
   <title>
    Marejeleo
   </title>
   <ref-list>
    <ref id="CR1">
     <label>
      1.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kerr
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales
      </article-title>
      <source>
       Int. J. Epidemiol.
      </source>
      <year>
       2023
      </year>
      <volume>
       52
      </volume>
      <fpage>
       22
      </fpage>
      <lpage>
       31
      </lpage>
      <pub-id pub-id-type="doi">
       10.1093/ije/dyac199
      </pub-id>
      <pub-id pub-id-type="pmid">
       36272418
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR2">
     <label>
      2.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Agrawal
        </surname>
        <given-names>
         U
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales
      </article-title>
      <source>
       Lancet
      </source>
      <year>
       2022
      </year>
      <volume>
       400
      </volume>
      <fpage>
       1305
      </fpage>
      <lpage>
       1320
      </lpage>
      <pub-id pub-id-type="doi">
       10.1016/S0140-6736(22)01656-7
      </pub-id>
      <pub-id pub-id-type="pmid">
       36244382
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9560746
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR3">
     <label>
      3.
     </label>
     <mixed-citation publication-type="other">
      Rough E., Coronavirus: Covid-19 booster vaccines frequently asked questions, 2022. [Online]. Available:
      <ext-link ext-link-type="uri" xlink:href="https://commonslibrary.parliament.uk/research-briefings/cbp-9332/">
       https://commonslibrary.parliament.uk/research-briefings/cbp-9332/
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR4">
     <label>
      4.
     </label>
     <mixed-citation publication-type="other">
      <italic>
       Greenbook Chapter:
      </italic>
      COVID-19 -
      <italic>
       SARS-CoV-2
      </italic>
      , no. April. 2023. [Online]. Available:
      <ext-link ext-link-type="uri" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1153300/Greenbook-chapter-14a-26April2023.pdf">
       https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1153300/Greenbook-chapter-14a-26April2023.pdf
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR5">
     <label>
      5.
     </label>
     <mixed-citation publication-type="other">
      World Health Organization, Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic, May 2023. Avilable:
      <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic">
       https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR6">
     <label>
      6.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Agrawal
        </surname>
        <given-names>
         U
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57 million people in Scotland (EAVE II): a prospective cohort study,
      </article-title>
      <source>
       Lancet Respir. Med.
      </source>
      <year>
       2021
      </year>
      <volume>
       9
      </volume>
      <fpage>
       1439
      </fpage>
      <lpage>
       1449
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXitFOlsLvJ
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/S2213-2600(21)00380-5
      </pub-id>
      <pub-id pub-id-type="pmid">
       34599903
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8480963
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR7">
     <label>
      7.
     </label>
     <mixed-citation publication-type="other">
      Office for National Statistics, Census 2021. Available:
      <ext-link ext-link-type="uri" xlink:href="https://census.gov.uk/">
       https://census.gov.uk/
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR8">
     <label>
      8.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Nafilyan
        </surname>
        <given-names>
         V
        </given-names>
       </name>
       <name>
        <surname>
         Ward
        </surname>
        <given-names>
         IL
        </given-names>
       </name>
       <name>
        <surname>
         Robertson
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <name>
        <surname>
         Sheikh
        </surname>
        <given-names>
         A
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Evaluation of risk factors for postbooster Omicron COVID-19 deaths in England
      </article-title>
      <source>
       JAMA Netw. Open
      </source>
      <year>
       2022
      </year>
      <volume>
       5
      </volume>
      <fpage>
       E2233446
      </fpage>
      <pub-id pub-id-type="doi">
       10.1001/jamanetworkopen.2022.33446
      </pub-id>
      <pub-id pub-id-type="pmid">
       36074469
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9459656
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR9">
     <label>
      9.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Smits
        </surname>
        <given-names>
         PD
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities
      </article-title>
      <source>
       Vaccine
      </source>
      <year>
       2023
      </year>
      <volume>
       41
      </volume>
      <fpage>
       2447
      </fpage>
      <lpage>
       2455
      </lpage>
      <pub-id pub-id-type="doi">
       10.1016/j.vaccine.2023.02.038
      </pub-id>
      <pub-id pub-id-type="pmid">
       36803895
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9933320
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR10">
     <label>
      10.
     </label>
     <mixed-citation publication-type="other">
      Office for National Statistics, Understanding consistency of ethnicity data recorded in health-related administrative datasets in England: 2011 to 2021, 2023.
      <ext-link ext-link-type="uri" xlink:href="https://www.ons.gov.uk/releases/understandingconsistencyofethnicitydatarecordedinhealthrelatedadministrativedatasetsinengland2011to2021">
       https://www.ons.gov.uk/releases/understandingconsistencyofethnicitydatarecordedinhealthrelatedadministrativedatasetsinengland2011to2021
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR11">
     <label>
      11.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Berec
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia
      </article-title>
      <source>
       PLoS One
      </source>
      <year>
       2022
      </year>
      <volume>
       17
      </volume>
      <fpage>
       1
      </fpage>
      <lpage>
       13
      </lpage>
      <pub-id pub-id-type="doi">
       10.1371/journal.pone.0270801
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR12">
     <label>
      12.
     </label>
     <mixed-citation publication-type="other">
      NHS, Personal Demographics Service. Available:
      <ext-link ext-link-type="uri" xlink:href="https://digital.nhs.uk/services/demographics">
       https://digital.nhs.uk/services/demographics
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR13">
     <label>
      13.
     </label>
     <mixed-citation publication-type="other">
      Office for National Statistics, Mortality statistics in England and Wales QMI, 2022. Available:
      <ext-link ext-link-type="uri" xlink:href="https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/methodologies/mortalitystatisticsinenglandandwalesqmi">
       https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/methodologies/mortalitystatisticsinenglandandwalesqmi
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR14">
     <label>
      14.
     </label>
     <mixed-citation publication-type="other">
      NHS England, The National Immunisation Management Service. Available:
      <ext-link ext-link-type="uri" xlink:href="https://www.england.nhs.uk/contact-us/privacy-notice/national-flu-vaccination-programme/#immunisation">
       https://www.england.nhs.uk/contact-us/privacy-notice/national-flu-vaccination-programme/#immunisation
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR15">
     <label>
      15.
     </label>
     <mixed-citation publication-type="other">
      World Health Organization, ICD-10 Version:2019. Available:
      <ext-link ext-link-type="uri" xlink:href="https://icd.who.int/browse10/2019/en#/U07.1">
       https://icd.who.int/browse10/2019/en#/U07.1
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR16">
     <label>
      16.
     </label>
     <mixed-citation publication-type="other">
      QCovid® risk calculator. Available:
      <ext-link ext-link-type="uri" xlink:href="https://www.qcovid.org/">
       https://www.qcovid.org/
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR17">
     <label>
      17.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Nafilyan
        </surname>
        <given-names>
         V
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       An external validation of the QCovid risk prediction algorithm for risk of mortality from COVID-19 in adults: a national validation cohort study in England
      </article-title>
      <source>
       Lancet Digit. Heal.
      </source>
      <year>
       2021
      </year>
      <volume>
       3
      </volume>
      <fpage>
       e425
      </fpage>
      <lpage>
       e433
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXis1SmsbY%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/S2589-7500(21)00080-7
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR18">
     <label>
      18.
     </label>
     <mixed-citation publication-type="other">
      Simpson C. R. et al. External validation of the QCovid risk prediction algorithm for risk of COVID-19 hospitalisation and mortality in adults: national validation cohort study in Scotland,
      <italic>
       Thorax
      </italic>
      , p. thoraxjnl-2021-217580, 2021,
      <ext-link ext-link-type="doi" xlink:href="10.1136/thoraxjnl-2021-217580">
       https://doi.org/10.1136/thoraxjnl-2021-217580
      </ext-link>
      .
     </mixed-citation>
    </ref>
   </ref-list>
  </ref-list>
  <app-group>
   <app id="App1" specific-use="web-only">
    <sec id="Sec11">
     <title>
      Taarifa za ziada
     </title>
     <p id="Par29">
      <supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2023_44276_MOESM1_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Supplementary Information
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM2" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2023_44276_MOESM2_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Peer Review File
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM3" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2023_44276_MOESM3_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Description of Additional Supplementary Files
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM4" xlink:title="Supplementary information">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2023_44276_MOESM4_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Supplementary Data 1
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM5" xlink:title="Supplementary information">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2023_44276_MOESM5_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Supplementary Data 2
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM6" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2023_44276_MOESM6_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Reporting Summary
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
    <sec id="Sec12">
     <title>
      Data ya chanzo
     </title>
     <p id="Par30">
      <supplementary-material content-type="local-data" id="MOESM7" xlink:title="Source data">
       <media mime-subtype="plain" mimetype="text" xlink:href="MediaObjects/41467_2023_44276_MOESM7_ESM.csv">
        <caption xml:lang="en">
         <p>
          Source Data
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
   </app>
  </app-group>
  <notes notes-type="ESMHint">
   <title>
    Taarifa za ziada
   </title>
   <p>
    The online version contains supplementary material available at
    <ext-link ext-link-type="doi" xlink:href="10.1038/s41467-023-44276-x">
     https://doi.org/10.1038/s41467-023-44276-x
    </ext-link>
    .
   </p>
  </notes>
  <notes notes-type="Misc">
   <p>
    <bold>
     Publisher’s note
    </bold>
    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
   </p>
  </notes>
 </back>
</article>
